EICHOR
● Recruiting
AMT-116 in Patients with Solid Tumors
Condition: Advanced Solid Tumors · Sponsor: Multitude Therapeutics Inc.
About this study
The purpose of this study is to evaluate the safety and efficacy of AMT-116 monotherapy in subjects with advanced solid tumors. The study is divided into two parts: the part I is dose escalation and the Part Ⅱ for expansion.
This description comes directly from the study's public registry record.
Talk to the study team
Yixuan Wang · +86-021-33560023 · yixuan.wang@multitudetherapeutics.com
Always discuss trial participation with your own doctor first.
Locations (7)
| Fujian Cancer Hospital | Fuzhou, Fujian, China | Recruiting |
| Dongguan People's Hospital | Dongguan, Guangdong, China | Not Yet Recruiting |
| Zhujiang Hospital of Southern Medical University(The Second Clinical Medical College) | Guangzhou, Guangdong, China | Recruiting |
| Guangxi Medical University Cancer Hospital | Nanning, Guangxi, China | Recruiting |
| Hunan Cancer Hospital | Changsha, Hunan, China | Recruiting |
| Zhejiang cancer hospital | Hangzhou, Zhejiang, China | Recruiting |
| The Second Affiliated Hospital and Yuying Childrens Hospital of Wenzhou Medical University | Wenzhou, Zhejiang, China | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06782334